Content created on
Interstitial cystitis is classified as a rare disease, and is very debilitating because of the severe pain caused by chronic inflammation of the bladder. There are very few treatments available, and they are generally ineffective against pain.
Irritable bowel syndrome affects 11% of the population. There are no specific treatments for abdominal pain associated with this condition.
Competitive advantages
- Good in vivo effectiveness against chronic and acute pain in interstitial cystitis and irritable bowel syndrome
- Persistent pain relief (> 48h)
- Anti-inflammatory effects for interstitial cystitis
Applications
Pain treatment for:
- Interstitial cystitis
- Irritable bowel syndrome
- Burning mouth syndrome
- BCG treatment for bladder cancer
- Endometriosis and neuropathies
Intellectual property
- Patent
Development stage
Validation of the technology in a real environment
Laboratory
IRSD INSERM
Description
The laboratory has identified new painkillers, particularly for irritable bowel syndrome and interstitial cystitis.
These molecules target the GABA receptor to inhibit visceral pain.
Technical specifications
- POC in vivo
- Good safety profile
- Does not cross the blood-brain barrier